Lewy body dementia is diagnosed through a combination of clinical evaluation, cognitive testing, and increasingly, specialized imaging and laboratory tests. There is no single test that confirms it. Instead, doctors look for a specific pattern of symptoms and use biomarkers to build confidence in the diagnosis. Because its symptoms overlap with both Alzheimer’s disease and Parkinson’s disease, getting an accurate diagnosis often takes time and requires clinicians familiar with the condition.
The Four Core Clinical Features
The current diagnostic framework, established by the DLB Consortium, requires progressive cognitive decline severe enough to interfere with daily life as a starting point. From there, doctors look for four core clinical features that distinguish Lewy body dementia from other forms of dementia.
Cognitive fluctuations are episodes where attention and alertness shift dramatically, sometimes within the same day. A person might seem sharp and engaged one hour, then confused or drowsy the next. These swings can look like delirium, but they recur without any infection or medication change to explain them. Caregivers often notice this before clinicians do.
Visual hallucinations are typically well-formed and detailed. People report seeing animals, people, or objects that aren’t there, and they can often describe them vividly. These hallucinations tend to appear early in the disease, which is unusual compared to Alzheimer’s, where hallucinations are rare until later stages.
Parkinsonism refers to movement symptoms like slowness, stiffness, or a shuffling walk. Only one of these motor signs needs to be present. Tremor can occur but is less prominent than in Parkinson’s disease itself.
REM sleep behavior disorder (RBD) was added as a core feature because it appears in roughly 76% of autopsy-confirmed cases, compared to just 4% in people without Lewy body pathology. RBD causes people to physically act out their dreams during sleep, sometimes kicking, punching, or shouting. It can begin years or even decades before any cognitive symptoms appear, making it one of the earliest warning signs.
For a “probable” diagnosis, a person needs dementia plus at least two of these four features, or one core feature supported by an indicative biomarker. A “possible” diagnosis requires only one core feature or one biomarker alone. Biomarkers alone, without any clinical symptoms, are not enough for a probable diagnosis.
How It Differs From Alzheimer’s and Parkinson’s
The cognitive profile in Lewy body dementia looks different from Alzheimer’s in ways that show up on neuropsychological testing. Memory loss dominates early Alzheimer’s, but in Lewy body dementia, the earliest and most striking deficits involve visuospatial skills and executive function. A simple example: the clock drawing test. People with Alzheimer’s typically struggle to draw a clock from memory but can copy one accurately. People with Lewy body dementia do poorly on both tasks, reflecting deeper visuospatial impairment. Block design tests and tasks requiring divided attention also tend to be significantly worse in Lewy body dementia than in Alzheimer’s at similar stages.
Distinguishing Lewy body dementia from Parkinson’s disease dementia is trickier because both involve the same underlying protein deposits in the brain. The practical dividing line is timing: if cognitive decline comes first or within a year of movement symptoms, the diagnosis is Lewy body dementia. If someone has had Parkinson’s disease for years before dementia develops, it’s classified as Parkinson’s disease dementia. This “one-year rule” is a clinical convention rather than a biological boundary, since the two conditions exist on a spectrum.
Imaging Tests Used in Diagnosis
Several brain imaging techniques help confirm or rule out Lewy body dementia when the clinical picture is ambiguous.
A DaTscan uses a small amount of radioactive tracer to visualize dopamine-producing cells in the brain. In Lewy body dementia, these cells are damaged, producing a characteristic pattern of reduced uptake. A meta-analysis of published studies found the scan has about 87% sensitivity and 94% specificity for distinguishing Lewy body dementia from other dementias. That high specificity means a positive result is quite reliable, though a negative result doesn’t completely rule it out.
FDG-PET scans, which measure brain metabolism, reveal a distinctive pattern in Lewy body dementia: reduced activity in the back of the brain (the parieto-occipital region) while areas like the posterior cingulate cortex remain relatively preserved. This preservation creates what’s called the “cingulate island sign.” It’s highly specific at around 90%, meaning when it’s present it strongly points to Lewy body dementia, but it only shows up in about 59% of cases, so its absence doesn’t rule the diagnosis out. In Alzheimer’s, by contrast, those preserved areas are typically among the first to show reduced metabolism.
Newer Biomarker Tests
The protein at the center of Lewy body dementia is alpha-synuclein, which misfolds and clumps inside brain cells. Until recently, the only way to confirm these deposits was through autopsy. That’s changing.
A test called a seed amplification assay can detect misfolded alpha-synuclein in spinal fluid. It works by using a tiny amount of the abnormal protein as a “seed” to trigger a detectable chain reaction in the lab. In studies of clinically diagnosed Lewy body dementia, the assay achieved about 87% accuracy. When researchers checked it against autopsy-confirmed cases, both sensitivity and specificity approached 100%. This test is becoming more widely available and represents one of the biggest advances in Lewy body diagnosis in recent years.
Skin biopsy is another emerging approach. Abnormal alpha-synuclein deposits in the small nerve fibers of the skin, and a punch biopsy can detect them. In research settings with patients who met standard clinical criteria for Lewy body dementia, over 95% tested positive. In a real-world clinical practice review that included more atypical presentations, the detection rate was lower (about 74%), with better results in earlier-stage disease (87%) than in more advanced dementia (60%). This suggests the test may be especially useful for catching the condition early.
Supportive Symptoms That Strengthen the Diagnosis
Beyond the four core features, several other symptoms help build the diagnostic picture. None of these alone points to Lewy body dementia, but when they cluster together alongside core features, they add confidence.
Autonomic dysfunction is common. This includes drops in blood pressure when standing (causing dizziness, lightheadedness, or fainting), constipation, urinary urgency or incontinence, and excessive sweating or loss of sweating. Studies have found that autonomic symptom scores are significantly higher in Lewy body dementia than in either Alzheimer’s disease or healthy aging. Some people experience these problems years before cognitive symptoms appear.
Other supportive features include excessive daytime sleepiness, a reduced sense of smell, sensitivity to antipsychotic medications (which can cause severe and dangerous reactions), depression, and apathy. Repeated falls and episodes of passing out also fit the pattern.
What the Diagnostic Process Looks Like
In practice, diagnosis usually starts with a detailed history from both the person and someone who knows them well, often a spouse or adult child. Caregivers are essential informants because they observe the fluctuations, sleep behavior, and hallucinations that the person may not remember or report. A neurological exam checks for parkinsonism. Cognitive testing evaluates memory, attention, visuospatial ability, and executive function, looking for the pattern that distinguishes Lewy body dementia from Alzheimer’s.
Blood tests and standard brain imaging (MRI or CT) are typically done to rule out other causes of cognitive decline, like thyroid problems, vitamin deficiencies, or strokes. If the clinical picture is suggestive but not definitive, a DaTscan, FDG-PET, or spinal fluid analysis may be ordered. Sleep studies can formally confirm REM sleep behavior disorder if it’s suspected but not clearly documented.
The process can take weeks to months, and misdiagnosis is common. Many people are initially told they have Alzheimer’s or Parkinson’s disease before the full symptom picture emerges. Seeking evaluation from a neurologist with experience in dementia subtypes can shorten this timeline significantly.